| pubmed-article:1786586 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1786586 | lifeskim:mentions | umls-concept:C0010592 | lld:lifeskim |
| pubmed-article:1786586 | lifeskim:mentions | umls-concept:C1707455 | lld:lifeskim |
| pubmed-article:1786586 | lifeskim:mentions | umls-concept:C0871161 | lld:lifeskim |
| pubmed-article:1786586 | lifeskim:mentions | umls-concept:C0699604 | lld:lifeskim |
| pubmed-article:1786586 | lifeskim:mentions | umls-concept:C0890152 | lld:lifeskim |
| pubmed-article:1786586 | pubmed:issue | 22-23 | lld:pubmed |
| pubmed-article:1786586 | pubmed:dateCreated | 1992-3-25 | lld:pubmed |
| pubmed-article:1786586 | pubmed:abstractText | An experimental comparative investigation provided evidence of identical immunomodulating properties of the Swiss cyclosporin A of Sandoz Company (Sandimmune) and the Czechoslovak cyclosporin of Galena Company (Consupren). Both preparations administered by the oral route to mice in low doses stimulated the reaction of the late hypersensitivity and in higher doses they inhibited markedly this reaction. Immunostimulation was also observed when influencing the host's reaction against the graft by low doses of the substance. The systemic reaction of the graft against the host was markedly suppressed by repeated doses. The development of antibody-producing cells in the spleen was markedly inhibited by high as well as small doses of the preparations. Inhibition of the formation of total antibodies is caused by inhibition of IgG formation, while IgM formation is enhanced and persists longer. This phenomenon is due to a block of the shift from IgM to IgG formation. In the allogenic tumour model both preparations caused a dose-dependent temporary immunosuppression. | lld:pubmed |
| pubmed-article:1786586 | pubmed:language | cze | lld:pubmed |
| pubmed-article:1786586 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1786586 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1786586 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1786586 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1786586 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:1786586 | pubmed:issn | 0008-7335 | lld:pubmed |
| pubmed-article:1786586 | pubmed:author | pubmed-author:NouzaKK | lld:pubmed |
| pubmed-article:1786586 | pubmed:author | pubmed-author:S?laKK | lld:pubmed |
| pubmed-article:1786586 | pubmed:author | pubmed-author:SvobodováMM | lld:pubmed |
| pubmed-article:1786586 | pubmed:author | pubmed-author:SobotkováEE | lld:pubmed |
| pubmed-article:1786586 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1786586 | pubmed:day | 29 | lld:pubmed |
| pubmed-article:1786586 | pubmed:volume | 130 | lld:pubmed |
| pubmed-article:1786586 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1786586 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1786586 | pubmed:pagination | 656-60 | lld:pubmed |
| pubmed-article:1786586 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:1786586 | pubmed:meshHeading | pubmed-meshheading:1786586-... | lld:pubmed |
| pubmed-article:1786586 | pubmed:meshHeading | pubmed-meshheading:1786586-... | lld:pubmed |
| pubmed-article:1786586 | pubmed:meshHeading | pubmed-meshheading:1786586-... | lld:pubmed |
| pubmed-article:1786586 | pubmed:meshHeading | pubmed-meshheading:1786586-... | lld:pubmed |
| pubmed-article:1786586 | pubmed:meshHeading | pubmed-meshheading:1786586-... | lld:pubmed |
| pubmed-article:1786586 | pubmed:meshHeading | pubmed-meshheading:1786586-... | lld:pubmed |
| pubmed-article:1786586 | pubmed:meshHeading | pubmed-meshheading:1786586-... | lld:pubmed |
| pubmed-article:1786586 | pubmed:meshHeading | pubmed-meshheading:1786586-... | lld:pubmed |
| pubmed-article:1786586 | pubmed:meshHeading | pubmed-meshheading:1786586-... | lld:pubmed |
| pubmed-article:1786586 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:1786586 | pubmed:articleTitle | [Comparison of the immunomodulating properties of the cyclosporin Sandimmune (Sandoz) with the newly developed Consupren (Galena)]. | lld:pubmed |
| pubmed-article:1786586 | pubmed:affiliation | Ustav experimentální medicíny CSAV, Praha. | lld:pubmed |
| pubmed-article:1786586 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1786586 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:1786586 | pubmed:publicationType | English Abstract | lld:pubmed |
